Skip to main content

Advertisement

Table 4 Inhibitory effect of (2E,5E)-2-(4-methoxybenzylidene)-5-(4-nitrobenzylidene) cyclopentanone (AK-1a) and (1E,4E)-4-(4-nitrobenzylidene)-1-(4-nitrophenyl)oct-1-en-3-one (AK-2a) and aspirin against arachidonic acid (AA) and adenosine diphosphate (ADP)-induced platelet aggregation

From: Synthesis, characterization, molecular docking, analgesic, antiplatelet and anticoagulant effects of dibenzylidene ketone derivatives

Treatment Agonist Inhibition of platelet aggregation (%) ± SEM IC50 (µM)
1 µM 3 µM 10 µM 30 µM 100 µM 300 µM 1000 µM
AK-1a AA 2.3 ± 0.06 7.2 ± 0.06 20.4 ± 0.06 33.2 ± 0.14 55.6 ± 0.20 67.1 ± 0.15 88.5 ± 0.18 65.2
ADP 1.81 ± 0.04 4.4 ± 0.04 13.4 ± 0.06 22.4 ± 0.04 31 ± 0.06 42.6 ± 0.06 54.1 ± 0.06 750.4
AK-2a AA 4.3 ± 0.07 10.5 ± 0.09 28 ± 0.15 42.7 ± 0.22 62.2 ± 0.08 78.9 ± 0.19 89.8 ± 0.13 37.7
ADP 4.4 ± 0.04 4.4 ± 0.07 14.2 ± 0.02 18.6 ± 0.06 30.2 ± 0.07 48.3 ± 0.12 56.8 ± 0.06 422
Aspirin AA 27.2 ± 0.18 36 ± 0.09 50.1 ± 0.16 59.7 ± 0.09 100 ± 0 100 ± 0 100 ± 0 10.01
ADP 3.6 ± 0.07 6.2 ± 0.09 19.1 ± 0.07 25 ± 0.06 32.8 ± 0.10 49.8 ± 0.12 56.9 ± 0.18 308.4
  1. Values shown as mean ± SEM, n = 4